Abstract
We investigated empagliflozin treatment effects on the composite of hospitalisation for heart failure (HHF) or CV death, total (first and recurrent) HHF, and estimated glomerular filtration rate (eGFR) slope in EMPEROR-Preserved participants with versus without ECG-documented or history of atrial fibrillation or atrial flutter (AF).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
